Bringing hope through science
Webcast - Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US
January 21, 2022, Oncopeptides announced that the Company has contacted the US Food and Drug Administration and rescinded the October 22, 2021, letter requesting voluntary withdrawal of the NDA of Pepaxto® in the US.
Investors, financial analysts and media are invited to participate in a webcast with a Q&A session on January 24, 2022, at 09:00 (CET).
The event will be hosted by CEO, Jakob Lindberg and CMO, Klaas Bakker. The presentation will be held in English.
Released
Interim report Q3 2021
Linda Holmström
Director of Investor Relations
Q4 report February 17, 2022
linda.holmstrom@oncopeptides.com
+46 70 873 40 95
Jakob interviewed by Di.TV - as new CEO about going forward
In conjunction with the anouncement of Jakob Lindberg as new CEO of Oncopeptides, he was interviewed by the Swedish economy TV channel Di.TV about the company's priorities going forward.
Jakob Lindberg appointed CEO
On November 15, Oncopeptides announced that the Board of Directors has appointed Jakob Lindberg as Chief Executive Officer, CEO of Oncopeptides. Jakob Lindberg replaces Marty J Duvall, who has been the CEO since July 1, 2020. These changes are effective immediately.
Press release -
Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US – no intent to market in the US at this time
Read press release
Upcoming events
-
-
-
Webcast - Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US
09:00 CET
-
08:00 CET
-
-
Journey of innovation
Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions.
Read more
Webcast - Oncopeptides withdraw Pepaxto in US, scale down organization and focus on R&D
October 22, Oncopeptides announced that the company has decided to withdraw Pepaxto® from the market in the US. The decision has been made after interactions and dialogue with the US Food and Drug Administration, FDA.
Investors, financial analysts, and media were invited to participate in a webcast including a Q&A the same day.
The event was hosted by CEO Marty J Duvall, CMO Klaas Bakker and CSO Jakob Lindberg. The presentation was held in English and was recorded.
Released
Annual Report 2020
Linda Holmström
Director of Investor Relations
linda.holmstrom@oncopeptides.com
+46 70 873 40 95
Vision of Oncopeptides
“Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
Cultures & Values
We are science and data driven, innovative and curious, making decisions based on systematic and thorough analyses.